Loading...
•
Mar 31, 2022
Zentalis Q1 2022 Earnings Report
Reported first quarter financial results and provided an operational update.
Key Takeaways
Zentalis Pharmaceuticals reported its first quarter 2022 financial results, highlighting clinical milestones and strategic partnerships, including initial data on ZN-c3 and a $25 million equity investment from Pfizer. Cash runway extended into Q1 2024.
Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR.
Received a $25 million equity investment from Pfizer, with plans to jointly advance clinical development of ZN-c3.
Initiated a potentially registrational Phase 1/2 study of ZN-d5 in patients with relapsed or refractory light chain (AL) amyloidosis.
Cash runway extended into Q1 2024, with Pfizer’s equity investment and budget reallocation.
Forward Guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of March 31, 2022, together with approximately $24.7 million of net proceeds from the April 2022 Pfizer equity investment, prioritization of the clinical development of ZN-c3 and ZN-d5, and budget reallocation, will be sufficient to fund its operating expenses and capital expenditures requirements into the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...